While Vor Biopharma Inc has overperformed by 1.45%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VOR rose by 89.19%, with highs and lows ranging from $3.29 to $0.13, whereas the simple moving average jumped by 113.50% in the last 200 days.
On June 30, 2025, H.C. Wainwright Upgraded Vor Biopharma Inc (NASDAQ: VOR) to Buy. A report published by Wedbush on July 26, 2022, Initiated its previous ‘Outperform’ rating for VOR. Goldman also rated VOR shares as ‘Neutral’, setting a target price of $6 on the company’s shares in an initiating report dated April 27, 2022. H.C. Wainwright Initiated an Buy rating on December 17, 2021, and assigned a price target of $26. Robert W. Baird initiated its ‘Outperform’ rating for VOR, as published in its report on December 03, 2021. Oppenheimer’s report from December 02, 2021 suggests a price prediction of $30 for VOR shares, giving the stock a ‘Outperform’ rating. JMP Securities also rated the stock as ‘Mkt Outperform’.
Analysis of Vor Biopharma Inc (VOR)
Vor Biopharma Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -125.43% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.88, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and VOR has an average volume of 18.29M. On a monthly basis, the volatility of the stock is set at 18.72%, whereas on a weekly basis, it is put at 11.94%, with a loss of -4.55% over the past seven days. Furthermore, long-term investors anticipate a median target price of $1.18, showing decline from the present price of $2.1, which can serve as yet another indication of whether VOR is worth investing in or should be passed over.
How Do You Analyze Vor Biopharma Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 48.06%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 42.12% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VOR shares are owned by institutional investors to the tune of 42.12% at present.
